Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer

Inclusion Criteria: * Written informed consent prior to any study activities * Age 18-75 * Histological/cytological and iconography confirmed squamous-celled oral/oropharyngeal cancer * Stage Ⅲ/Ⅳa (T1-2, N1-2, M0 or T3-4, N0-2, M0, AJCC 2010), operable disease * Karnofsky performance status (KPS) ≥70 * Adequate hematologic function: Neutrophils ≥1,500/mm\^3, WBC \>4,000/mm\^3, Hb \> 10 g/dL, platelet count \>100,000/mm\^3 * Hepatic function: ALAT/ASAT \<2.5 times the upper limit of normal (ULN), bilirubin \<1.5 x ULN * Renal function: serum creatinine \<1.5 x ULN * Life expectancy ≥6 months Exclusion Criteria: * Evidence of distant metastatic disease and other oropharyngeal cancers * Surgical procedure of the primary tumor or lymph nodes (except diagnostic biopsy) before study treatment * Previous radiotherapy for the primary tumor or lymph nodes * Previous exposure to epidermal growth factor-targeted therapy * Prior chemotherapy or immunotherapy for the primary tumor * Other previous malignancy within 5 years, except non-melanoma skin cancer or pre-invasive carcinoma of the cervix * Any investigational agent prior to the 1st study medication * Participation in another clinical study within the 30 days prior to Inclusion in this study. * Peripheral neuropathy \>grade 1 * Known grade 3 or 4 allergic reaction to any of the study treatment * History of severe pulmonary or cardiac disease * Creatinine Clearance \<30 ml/min * Know drug abuse /alcohol abuse * Legal incapacity or limited legal capacity * Active systemic infection * Medical or psychiatric illness, which in the investigators' opinions, would not permit the subject to complete or fully and completely understand the risks and potential complications of the study * Concurrent chronic systemic immune therapy or hormone therapy not indicated in the study protocol * Pregnancy (confirmed by serum or urine β-HCG) or lactation period * Severe cardiac disease such as heart failure, clinical relevant cardiac dysrhythmias, coronary artery disease or myocardial infarction within the last 12 months